[1]胡 鹏,吴成璧.耐药肺结核患者治疗结局及费用补偿影响因素分析[J].卫生经济研究,2024,41(08):41-44.
　HU Peng,WU Chengbi.Analysis of Influencing Factors of Treatment Outcomes and Cost Compensation in Patients with Drug-resistant Pulmonary Tuberculosis[J].Journal Press of Health Economics Research,2024,41(08):41-44.
点击复制

耐药肺结核患者治疗结局及费用补偿影响因素分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年08期
页码:
41-44
栏目:
成本与费用
出版日期:
2024-08-01

文章信息/Info

Title:
Analysis of Influencing Factors of Treatment Outcomes and Cost Compensation in Patients with Drug-resistant Pulmonary Tuberculosis
作者:
胡 鹏1; 吴成璧1
1.武汉市红十字会医院，湖北 武汉 430015
Author(s):
HU Peng;  WU Chengbi
Wuhan Red Cross Hospital, Wuhan Hubei 430015, China
关键词:
耐药肺结核; 治疗结局; 影响因素; 医疗保障
Keywords:
drug-resistant pulmonary tuberculosis;  treatment outcome;  influencing factors;  medical security
分类号:
R19
文献标志码:
A
摘要:
目的：分析耐药肺结核患者治疗结局，从费用补偿角度探究其影响因素。方法：采用描述性分析法分析耐药肺结核患者的费用水平以及补偿情况，采用单因素分析、二元Logistics回归等方法分析患者治疗结局的影响因素。结果：耐药肺结核患者全疗程医疗费用高达69 190.88元，实际补偿比为35.62%，有公共卫生项目补助的患者实际补偿比远高于无补助患者，良性结局的患者占64.3%，老年患者、男性患者的治疗结局较差，门诊实际补偿比越高、有公共卫生项目补助、获得医疗救助患者的治疗结局更优。结论：耐药肺结核患者的费用负担较重，可通过提升医保补偿水平、完善项目补助政策、扩大医疗救助覆盖面，提高费用补偿水平，改善患者治疗结局。
Abstract:
Objective To analyze the treatment outcome of patients with drug-resistant pulmonary tuberculosis, and explore the influencing factors from the perspective of cost compensation. Methods Descriptive analysis was used to analyze the cost level and compensation of patients with drug-resistant pulmonary tuberculosis, and univariate analysis and binary logistics regression were used to analyze the influencing factors of treatment outcomes of the patients. Results The total medical treatment cost of patients with drug-resistant pulmonary tuberculosis was as high as 69 190.88 yuan, and the actual compensation ratio was 35.62%. The actual compensation ratio of patients with subsidies from special public health programs was much higher than that of patients without subsidies. The benign outcome accounted for 64.3% of the patients, and the treatment outcome of the elderly patients and male patients was significantly worse. The higher actual compensation ratio of the outpatient clinic, the more subsidies of the public health programs, with medical aid, the better treatment outcomes for patients. Conclusion The cost burden of patients with drug-resistant pulmonary tuberculosis is heavy. It is necessary to raise the level of health insurance compensation, improve the program subsidy policy, and expand the coverage of medical aid, so as to increase the level of cost compensation and improve the treatment outcome of patients.

参考文献/References:

[1] World Health Organization. Global tuberculosis report 2023[EB/OL].https://www.who.int/publications/i/item/9789240083851.
[2] 王宇.全国第五次结核病流行病学抽样调查资料汇编[M].北京：军事医学科学出版社，2011.
[3] 尤媛媛，张国龙，陈裕.120例初治耐多药肺结核患者治疗依从性的影响因素分析[J].中国防痨杂志，2020，42（03）：249-254.
[4] Wen S,Yin J,Sun Q.Impacts of social support on the treatment outcomes of drug-resistant tuberculosis:a systematic review and meta-analysis[J/OL].BMJ Open,2020, 10(10):e036985.
[5] 蒋泽顺，杨正贵，李江平，等.宁夏结核病治疗转归影响因素分析及预测模型的建立[J].现代预防医学，2021，48（16）：2905-2910.
[6] 杨丹，文进，刘年强，等.新疆维吾尔族人群肺结核治疗结局影响因素研究[J].中国全科医学，2019，22（12）：1413-1418.
[7] 徐静，姜爽爽，郑海伦，等.290例耐药肺结核高危人群耐药情况及治疗结果分析[J/OL].中国防痨杂志，2023，45（03）：323-327.
[8] 殷美静，宋立婷，张艳，等.西安市96例耐多药肺结核治疗转归现况及其影响因素分析[J].预防医学情报杂志，2020，36（10）： 1285-1290.
[9] 刘俊萍，孙彦波，张淑兰，等.中国耐多药结核不良治疗结局情况的Meta分析[J].中国循证医学杂志，2021，21（10）：1174-1178.
[10] 骆梦醒，邹欣，高雅娴，等.结核病合并基础疾病患者的抗结核治疗效果及肺部损伤分析[J].上海交通大学学报（医学版）， 2023，43（08）：1017-1023.
[11] 王硕，何梦雅，张艳秋，等.1165例耐多药和广泛耐药肺结核患者治疗结局及影响因素分析[J].疾病监测，2024，39（01）：1-9.
[12] Ahmad N,Ahuja S D,Akkerman O W,et al.Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis:an individual patient data meta-analysis[J].The Lancet,2018,392(10150): 821-834.
[13] 付鑫，仲崇桥，杨皓舒.江苏省连云港市2010—2019年老年肺结核流行特征[J].中国热带医学，2022，22（01）：54-57，83.
[14] 常玉雪，周玉兰，陈之源，等.乌鲁木齐市老年结核患者健康相关生命质量评价[J].现代预防医学，2020，47（06）：1062-1066.
[15] 张玲，林昌锋，孙霞，等.海南省三亚地区肺结核社会经济学情况调查及影响治愈因素分析[J].中国卫生统计，2023，40（05）： 762-764.
[16] Long Q,Smith H,Zhang T,et al.Patient medical costs for tuberculosis treatment and impact on adherence in China:a systematic review[J].BMC Public Health,2011,11(01):393.

更新日期/Last Update: 2024-08-01